Consensus $23.03M. Sees FY22 gross margin 48%-52%. "We are continuing to execute to our plan of being the leader in benchtop automation for synthetic biology, multiomics and next gen sequencing," said Todd Nelson, CEO and founder of Telesis Bio.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DNAY:
- Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8
- Telesis Bio, Cellibre announce collaboration on development of BioXp DBC
- Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrument
- Codex DNA changing corporate name to Telesis Bio
- Codex DNA Expands Application of Proprietary Error Correction Technology
